Navigation Links
Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results

AUSTIN, Texas, Feb. 6, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the fourth quarter and year ended December 31, 2011.  Financial and operating highlights include the following:


  • Consolidated fourth quarter 2011 revenue was $47.9 million, a 16 percent increase over the fourth quarter of 2010; full-year 2011 revenue was $184.3 million, a 30 percent increase over 2010
  • Fourth quarter 2011 assay sales of $16.4 million grew 77 percent over the fourth quarter of 2010; full-year 2011 assay revenue was $48.7 million, a 51 percent increase over 2010 and included a contribution from EraGen Biosciences, Inc. that exceeded the high end of our expectations for 2011 revenue
  • Fourth quarter 2011 shipments of 307 multiplexing analyzers that included 114 MAGPIX® systems, resulted in cumulative life-to-date multiplexing analyzer shipments of 8,678
  • Consolidated gross profit margin of 67.9 percent for the fourth quarter of 2011, which included the negative impact on gross profit margin resulting from the recording of EraGen inventory acquired at fair value on the date of acquisition  
  • Operating income for the fourth quarter of 2011 was $3.9 million. Included in this amount is approximately $1.1 million in incremental expense resulting from recording the EraGen inventory acquired at fair value on the date of acquisition and approximately $0.5 million in acquisition/integration costs associated with EraGen. Excluding the revaluing of EraGen inventory and acquisition costs, non-GAAP operating income for the fourth quarter of 2011 was $5.5 million, a $0.4 million increase over the fourth quarter of 2010
  • GAAP net income for the fourth quarter of 2011 was $3.4 million, or $0.08 per diluted share. GAAP net income for the full-year 2011 was $14.5 million or $0.34 per diluted share, compared to full-year 2010 net income of $5.2 million or $0.12 per diluted share. Excluding the aforementioned fair value adjustment to EraGen inventory and integration expenses, non-GAAP net income for the fourth quarter and 2011 was $4.8 million and $19.3 million or $0.11 and $0.45 per diluted share, respectively

  • "Luminex's strong fourth quarter performance completed a year that was full of achievements," said Patrick J. Balthrop, president and chief executive officer of Luminex.  "In 2011, Luminex delivered 30 percent total revenue growth, driven by our higher margin revenue categories; assays, consumables, and royalties. The assay group, led by our Cystic Fibrosis and Respiratory Viral Panel franchises, and a healthy contribution from our acquisition of EraGen Biosciences, generated 51 percent growth over 2010. As forecasted, consumable revenue in the second half of the year decelerated from an exceptionally strong first half, yet for the full year, consumable revenue grew 38 percent over 2010. Finally, we recognized 30 percent growth in royalty revenue in 2011, which reflects the continuing strong commitment to and investment in our proprietary technology by our key partners." 

    "During 2011 we achieved several significant milestones, including the launch of our novel xTAG® Gastrointestinal Pathogen Panel in Europe, FDA clearance of our xTAG RVP FAST assay, and the acquisition of EraGen Biosciences. We believe these new products will begin to make a meaningful contribution in 2012," added Balthrop. "We are excited about the prospects for growth and remain focused on delivering innovative, high performance solutions to our customers. We believe our focus on the customer will continue to drive long-term value for our shareholders," Balthrop concluded. REVENUE SUMMARY(in thousands, except percentages)Three Months EndedDecember 31,Variance20112010($)(%)(unaudited)System sales

    $  10,449$  10,304$
    451%Consumable sales

    10,09311,954(1,861)-16%Royalty revenue

    7,0876,0441,04317%Assay revenue

    16,4019,2427,15977%All other revenue

    3,8393,6461935%$  47,869$  41,190$  6,67916%Twelve Months EndedDecember 31,Variance20112010($)(%)(unaudited)System sales

    $  35,901$  32,984$  2,9179%Consumable sales

    55,45740,10415,35338%Royalty revenue

    29,20522,4146,79130%Assay revenue

    48,67032,20416,46651%All other revenue

    15,10613,8511,2559%$184,339$141,557$42,78230%LUMINEX CORPORATIONREPORTABLE SEGMENT HIGHLIGHTS(in thousands, except percentages)Three Months EndedDecember 31,Variance20112010($)(%)(unaudited)RevenueTechnology and strategic partnerships

    $  29,715$  30,550$
    (835)-3%Assays and related products

    18,15410,6407,51471%Total Revenue

    47,86941,1906,67916%Operating income (loss)Technology and strategic partnerships

    4,2395,872(1,633)-28%Assays and related products

    (307)(789)48261%Total Operating income

    3,9325,083(1,151)-23%Twelve Months EndedDecember 31,Variance20112010($)(%)(unaudited)RevenueTechnology and strategic partnerships

    $127,779$105,586$22,19321%Assays and related products

    56,56035,97120,58957%Total Revenue

    184,339141,55742,78230%Operating income (loss)Technology and strategic partnerships

    29,89515,97713,91887%Assays and related products

    (6,052)(4,726)(1,326)-28%Total Operating income

    23,84311,25112,592112%FINANCIAL OUTLOOK AND GUIDANCE The Company intends to provide annual revenue guidance, to be updated, as appropriate, at each quarterly reporting period. Guidance for fiscal 2012 is as follows:

  • The Company expects fiscal 2012 revenue to be between $205 million to $215 million, or an increase of between 11 to 17 percent over reported 2011 revenue.

  • CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the fourth quarter ended December 31, 2011, on Monday, February 6, 2012, at 5:00 p.m. Eastern time/ 4:00 p.m. Central time.  The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at

    Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base; expanded distribution for our MAGPIX system; the development progress of our NeoPlex4 assay product; market acceptance of our RVP FAST and GPP assay products; integration of EraGen Biosciences, Inc.; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2012 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex's foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets, into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2012 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.Contacts:

    Harriss T. Currie

    Matthew ScaloVice President, Finance and Chief Financial Officer

    Sr. Director of Investor Relations512-219-8020 LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)December 31,December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    89,487Restricted cash

    1,0061,002Short-term investments

    42,57428,404Accounts receivable, net

    23,01620,936Inventories, net

    24,57924,932Deferred income taxes

    5,9914,225Prepaids and other

    3,5292,732Total current assets

    158,977171,718Property and equipment, net

    25,19222,084Intangible assets, net

    29,43712,944Deferred income taxes

    12,8176,363Long-term investments



    7,3104,430Total assets

    265,810LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    7,621Accrued liabilities

    11,0477,444Deferred revenue

    4,0573,866Current portion of long term debt

    999849Total current liabilities

    22,04419,780Long-term debt

    2,5733,351Deferred revenue


    3,8313,511Total liabilities

    31,79230,945Stockholders' equity:Common stock

    4141Additional paid-in capital

    297,104295,422Accumulated other comprehensive gain

    9841,150Accumulated deficit

    (47,274)(61,748)Total stockholders' equity

    250,855234,865Total liabilities and stockholders' equity

    265,810LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedTwelve Months EndedDecember 31,December 31,2011201020112010(unaudited)(unaudited)Revenue

    $ 47,869$ 41,190$
    84,339$ 141,557Cost of revenue

    15,35012,61158,84945,180Gross profit

    32,51928,579125,49096,377Operating expenses:Research and development

    9,8827,84133,39426,843Selling, general and administrative

    17,61015,08164,87856,119Amortization of acquired intangible assets

    1,0955743,3752,164Total operating expenses

    28,58723,496101,64785,126Income from operations

    3,9325,08323,84311,251Interest expense from long-term debt

    (73)(85)(308)(419)Other income, net

    107119394519Income before income taxes

    3,9665,11723,92911,351Income taxes

    (524)(1,918)(9,455)(6,120)Net income

    $  3,442$  3,199$
    5,231Net income per share, basic

    .13Shares used in computing net income per share, basic

    41,15341,19941,26241,030Net income per share, diluted

    .12Shares used in computing net income per share, diluted

    42,37642,67142,53742,438The Company has reclassified certain amounts previously classified as a component of selling, general and administrative expenses to research and development expenses to conform to the current period presentation. This reclassification was $1.1 million and $3.4 million for the three and twelve months ended December 31, 2010, and was not material to the Company's consolidated financial statements. LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)Three Months EndedTwelve Months EndedDecember 31,December 31,2011201020112010(unaudited)(unaudited)Cash flows from operating activities:Net income

    $   3,442$   3,199$
    4,474$   5,231Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization

    3,4622,40411,8878,898Stock-based compensation

    3,1162,51111,4179,436Deferred income tax benefit (expense)

    (2,058)2,101(592)5,591Excess income tax benefit from employee stock-based awards


    354(140)232709Changes in operating assets and liabilities:Accounts receivable, net

    (2,303)(1,867)(899)2,199Inventories, net

    1,410(746)4,783(5,811)Other assets

    (575)(178)(1,279)(332)Accounts payable

    (786)646(2,680)(1,776)Accrued liabilities

    5,1315319,324(506)Deferred revenue

    (283)(654)(763)536Net cash provided by operating activities

    9,6419,09738,29024,175Cash flows from investing activities:Purchases of available-for-sale securities

    (13,474)(3,008)(47,743)(29,673)Maturities of available-for-sale securities

    8,0377,50033,75323,693Purchase of property and equipment

    (2,434)(2,540)(9,554)(11,102)Business acquisition consideration, net of cash acquired

    -24(33,914)(5,012)Increase in restricted cash

    ---(1,000)Purchase of cost method investment

    -(5)(2,000)(2,081)Acquired technology rights

    (1,331)(625)(1,857)(1,825)Net cash (used in) provided by investing activities

    (9,202)1,346(61,315)(27,000)Cash flows from financing activities:Payments on debt

    --(885)(895)Proceeds from issuance of common stock

    1097263,5432,173Payments for stock repurchases

    (8,600)-(18,340)-Excess income tax benefit from employee stock-based awards

    1,269(1,290)7,614-Net cash (used in) provided by financing activities

    (7,222)(564)(8,068)1,278Effect of foreign currency exchange rate on cash

    (16)379(112)191Change in cash and cash equivalents

    (6,799)10,258(31,205)(1,356)Cash and cash equivalents, beginning of period

    65,08179,22989,48790,843Cash and cash equivalents, end of period

    $ 58,282$ 89,487$
    58,282$ 89,487LUMINEX CORPORATIONNON-GAAP RECONCILIATION(in thousands)Three Months EndedTwelve Months EndedDecember 31,December 31,2011201020112010(unaudited)(unaudited)Income from operations

    ,251Fair value markup of inventory

    1,091-3,321-Acquisition/Integration costs

    500-2,119-Adjusted income from operations

    ,251LUMINEX CORPORATIONNON-GAAP RECONCILIATION(in thousands, except per share amounts)Three Months EndedTwelve Months EndedDecember 31,December 31,2011201020112010(unaudited)(unaudited)Net income

    $ 3,442$ 3,199$  14,474$ 5,231Fair value markup of inventory

    1,091-3,321-Acquisition/Integration costs

    500-2,119-Income tax effect

    (222)(638)Adjusted net income

    $ 4,811$ 3,199$  19,276$ 5,231Adjusted net income per share, basic

    $   0.12$   0.08$
    .47$   0.13Shares used in computing net income per share, basic

    41,15341,19941,26241,030Adjusted net income per share, diluted

    $   0.11$   0.07$
    .45$   0.12Shares used in computing net income per share, diluted


    SOURCE Luminex Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
    2. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
    3. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
    4. Luminex Corporation to Present at UBS Global Life Sciences Conference
    5. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
    6. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
    7. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
    8. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
    9. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
    10. Luminex Corporation Reports Third Quarter 2010 Results
    11. Luminex Corporation to Present at Stephens Fall Investment Conference
    Post Your Comments:
    (Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
    (Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
    (Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
    (Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
    (Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
    (Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
    Breaking Medicine News(10 mins):